Centre puts stricter controls on sale of 4 CNS drugs over abuse concerns
Move follows expert concerns over potential misuse and intoxication; retailers will have to maintain detailed sales records for the four CNS medicines under Schedule H1
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
